Ideas floated by the Trump Administration and Democrats in Congress aim to expand access to fertility treatment as an essential health benefit. But an influx of patients could collide with an already-brittle system of 430,000 annual cycles, 5,000 embryologists, and long-overdue lab upgrades. The post IVF Coverage Proposals Could Squeeze U.S. Fertility Clinics Without Improving…
El año pasado fue difícil para los agricultores. Ante la caída de los precios de cultivos como el maíz y la soya, el aumento de los costos de insumos como fertilizantes y semillas, así como los aranceles impuestos por el expresidente Donald Trump y el desmantelamiento de la Agencia de los Estados Unidos para el…
Reimbursement issues in the healthcare industry are complex, but reimbursement is essential for healthcare organizations. Proper reimbursement allows providers to run operations efficiently and deliver consistent, high-quality patient care. It also enables organizations to invest in technologies that advance their operations. Read on to learn more about the causes of reimbursement issues and discover the…
Legal case involves major implications for health insurance coverage nationwide
Healthcare organizations face challenges with siloed data, causing repeated paperwork
CMS Administrator Dr. Mehmet Oz said that Medicaid’s rapid spending growth is unsustainable and criticized state financing tactics that let providers and governments “game” the system for extra federal funds. He said CMS is shifting its fraud strategy to follow the flow of money rather than just individual offenders in an effort to ensure health…
KFF is tracking the Medicaid provisions in the 2025 federal budget bill, including new Medicaid work and verification requirements and a reduction in the expansion match rate for states that use their own funds to cover undocumented immigrants.
Ampersand Biomedicines’ map of all tissue in the human body reveals “addresses,” identifying markers on disease targets that are not found on healthy tissue. The company aims to improve the targeting of biologic drugs in order to reduce on-target, off-tissue toxicity. The post Flagship’s Ampersand Bio Adds $65M to Solve One of the Top Challenges…
Antares Therapeutics spun off of Scorpion Therapeutics, a clinical-stage biotech that Eli Lilly acquired earlier this year. Like Scorpion, Antares is developing small molecules that go after undruggable targets in cancer. The post Cancer Drug Startup Antares Unveils $177M to Pick Up Where Scorpion Therapeutics Left Off appeared first on MedCity News.